Prostate Cancer - Results from #1320

Additional COBRA Results: SAR-bisPSMA Detects Lesions in the 2-Millimetre Range March 6, 2024

Critical evaluation of artificial intelligence as a digital twin of pathologists for prostate cancer pathology. March 6, 2024

MRI-guided radiotherapy in twenty fractions for localised prostate cancer; results from the MOMENTUM study. March 6, 2024

Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance). March 6, 2024

Complications of immuno-oncology care: what urologist should know. March 6, 2024

The cost-effectiveness of germline BRCA testing-guided olaparib treatment in metastatic castration resistant prostate cancer. March 6, 2024

ArteraAI Announced as the First-and-Only Predictive Test for Therapy Personalization in the 2024 NCCN Guidelines® for Prostate Cancer March 5, 2024

Association between patient ethnicity and prostate cancer diagnosis following a prostate-specific antigen test: a cohort study of 730,000 men in primary care in the UK. March 5, 2024

The Incremental Role of Magnetic Resonance Imaging for Prostate Cancer Staging before Radical Prostatectomy. March 5, 2024

A Grading System for the Assessment of Risk of Extraprostatic Extension of Prostate Cancer at Multiparametric MRI. March 5, 2024

Urologists' and general practitioners' knowledge, beliefs and practice relevant for opportunistic prostate cancer screening: a PRISMA-compliant systematic review. March 5, 2024

Development of Novel Models of Aggressive Variants of Castration-resistant Prostate Cancer. March 5, 2024

Combining magnetic resonance imaging with a multi-ancestry polygenic risk score to improve identification of clinically-significant prostate cancer. March 5, 2024

A multidisciplinary approach to address unmet needs in the management of patients with non-metastatic castration-resistant prostate cancer. March 5, 2024

Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel. March 5, 2024

Ultrasensitive Detection of Circulating Tumour DNA enriches for Patients with a Greater Risk of Recurrence of Clinically Localised Prostate Cancer. March 4, 2024

Racial disparities in diagnosis and treatment of depression Associated with androgen deprivation therapy for prostate cancer. March 4, 2024

High dimensional analyses reveal IL-15 enhances activation of Sipuleucel-T lymphocyte subsets and reverses immunoresistance. March 4, 2024

A Phase I Trial of Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer After Brachytherapy. March 4, 2024

Secondary analysis of late major gastrointestinal and genitourinary toxicities in unfavorable-risk prostate cancer patients receiving docetaxel: Insights from a randomized trial. March 4, 2024

Page 67 of 1439